22nd Century Group Inc(XXII) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 6 at 4:15 AM ET (Korea 11/6 18:15)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -37364.29 | Insider Own | 16.04% | Shs Outstand | 0.3M | Perf Week | -60.76% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.3M | Perf Month | -96.27% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 0.35% | Short Float | 0.23% | Perf Quarter | -99.22% |
| Income | -0.03B | P/S | 0.04 | EPS this Y | - | Inst Trans | 0.86% | Short Ratio | 0 | Perf Half Y | -99.77% |
| Sales | 0.01B | P/B | 0 | EPS next 5Y | - | ROA | -52.86% | Short Interest | 0.00M | Perf YTD | -99.99% |
| Book/sh | 2150.15 | P/C | 0.11 | EPS past 3/5Y | 98.99% 87.27% | ROE | -105.73% | 52W High | -99.99% ($23838.00) | Perf Year | -99.99% |
| Cash/sh | 18.25 | P/FCF | - | Sales past 3/5Y | -24.27% -8.95% | ROIC | -20.03% | 52W Low | -6.53% ($2.06) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.95% | Gross Margin | -22.15% | Volatility(W/M) | 31.03% 32.38% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -0.25 | Sales Y/Y TTM | -27.44% | Oper. Margin | -84% | ATR (14) | 6.08 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 1.9 | EPS Q/Q | 97.45% | Profit Margin | -237.82% | RSI (14) | 16.62 | Recom | 2 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.61 | Sales Q/Q | -29.86% | SMA20 | -88.34% ($16.55) | Beta | 0.78 | Target Price | $156600 |
| Payout | - | Debt/Eq | 0.09 | Earnings | 2026/11/16 | SMA50 | -97.17% ($68.2) | Rel Volume | 1.32 | Prev Close | $2.44 |
| Employees | 32 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | - | SMA200 | -99.9% ($1930) | Avg Volume(3M) | 0.27M | Price | $1.93 |
| IPO | 2011/1/26 | Option/Short | No/Yes | Trades | 6601 | Volume | 358,384 | Change | -20.77% |
An innovative life sciences company dedicated to reducing the harm caused by smoking. It has pioneered a new product category with FDA-approved low-nicotine cigarettes designed to reduce smokers' health damage and lower nicotine addiction.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded more than usual. That is 132% of its average volume.
Next earnings report: November 16
10 days to go.
XXII has a sound balance sheet but weak earning power
Of every $100 in sales, $84.00 is lost.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $4. Peers typically go for $42.
Tap to view numbers
Not enough quarters to judge yet
Only 2 quarter(s) reported, so no grade yet.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +56% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
It ranks #11 of 11 in the industry
Based on market cap of $1M.
UVV#7 Universal Corp $1B PER 54.7 
ISPR#8 Ispire Technology Inc $83M PER - 
RYM#9 RYTHM Inc $35M PER - 
GNLN#10 Greenlane Holdings Inc $1M PER - XXII#11 22nd Century Group Inc $1M PER - 
FAQ
What kind of company is XXII?
XXII belongs to the Consumer Defensive sector and operates in the Tobacco industry.
What is the market cap of XXII?
The market cap of XXII is approximately $1M, ranking 5,880 within its sector.
What is the 52-week high and low for XXII?
XXII has recorded a 52-week high of $23838.00 and a low of $2.06.
